These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36692912)

  • 1. Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?
    Sirrs S; Anderson H; Jiwani B; Lynd LD; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):10-26. PubMed ID: 36692912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?
    Lexchin J; Sirrs S
    Healthc Policy; 2024 Aug; 19(4):19-26. PubMed ID: 39229659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
    Jenei K; Gyawali B
    Healthc Pap; 2023 Jan; 21(1):44-51. PubMed ID: 36692916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustainable rare diseases business and drug access: no time for misconceptions.
    Rollet P; Lemoine A; Dunoyer M
    Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone.
    Sirrs S; Anderson H; Jiwani B; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):74-80. PubMed ID: 36692920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
    Kawakami A; Masamune K
    Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.